Big Idea CONNECTpreneur Forum

Washington DC - IN PERSON

September 11, 2025

CONNECTpreneur Forums are bi-monthly in person networking mashups, which have been attended by over 35,000 business leaders over the past 14 years.

Space is very limited at this venue, and this will another Sold Out in person event, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- We are capping attendance at 180+ business leaders, including 75+ angels and private investors, family offices, etc.

- Showcase of Emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- Heavy networking before, during, and after the event

Beverages and light fare will be provided.

Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor reception on Monday, September 8 in NYC featuring Intrommune, a consumer health company with a revolutionary approach to allergy prevention.

Intrommune’s patented oral mucosal immunotherapy (OMIT) platform delivers allergenic proteins via a simple, familiar routine: brushing your teeth. This daily-use toothpaste is designed to train the immune system and help prevent life-threatening food allergies—starting with peanuts and tree nuts.

This elegant solution bridges the gap between biotech and consumer health, offering a safe, effective, and scalable approach to a massive and underserved global market.

💡 The Investment Opportunity:

• Now raising $4 million

• Minimum investment: $100,000 (lower amounts may be considered at Management’s discretion)

• Early investors within 30 days receive preferential terms

• NASDAQ IPO targeted within 36 months

Why Intrommune?

Validated Science, Consumer SimplicityI

n the published Phase 1 OMEGA study for peanut allergy, patients achieved 97% adherence with zero dropouts and no cases of anaphylaxis from the therapy—a rare combination of strong clinical results and unmatched user friendliness.

Enormous Market Need

Over 33 million Americans suffer from food allergies, yet treatment options remain limited. Early and consistent food exposure has been shown to decrease food allergies by over 80%. OMIT offers a daily, non-invasive food exposure toothpaste with wide appeal for parents, caregivers, and at-risk individuals.

First-Mover Advantage

No other company combines biotech-grade science with a consumer-ready delivery format—positioning Intrommune as the clear category creator in oral allergy prevention.

Experienced Leadership

CEO Michael Nelson brings decades of operational and financing experience in healthcare, and the company is advised by Dr. Sharon Chinthrajah, a nationally recognized allergy expert.

🎯 Why You Should Attend:

This is a rare opportunity to back a biotech-powered consumer product that’s validated, scalable, and de-risked—and to meet the team behind it in a private setting.

Join a select group of investors for an insider’s view into Intrommune’s next chapter and how this product could become a daily staple for millions of families.

📍 Event Details – Strictly Limited:

Location: The Capital Grille,

200 Park Ave,

New York, NY 10166

Date: September 8, 2025

Time: 5:30pm EDT

This event is exclusively for accredited investors, family offices, and advisors.

📩 RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

Warm regards,

Tien Wong

CEO

Opus8, Inc.

Virtual Rocket Pitch + Power Networking by CONNECTpreneur Investor Network

Thursday, August 28, 2025, 11:00am EDT

We will email you the LINK to this special event on the evening of August 27th, as well as the morning of August 28th.

About this Event:

CONNECTpreneur Virtual Rocket Pitch events are the World's Largest investor pitch events, with the greatest number of accredited investors, VCs, private investors and angels.

This will be our 135th event (68th Virtual) over the last 14 years.

CONNECTpreneur is a bi-monthly networking mashup that has been attended by 30,000+ business leaders over the past 14 years. Our events are cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Program Highlights:

- "Virtual Networking" pre and post-program - via Private Message, and Breakout Rooms

- We feature Breakout Rooms after the Pitch portion of the events. Each Breakout Room is hosted by a Presenting Company. Attendees will be able to enter and leave any Breakout Room at their convenience.

- Who will be online? We expect 400+ business leaders, including 150+ CEOs & Founders, as well as 150+ angels & VCs from around the USA.

- "Rocket Pitch" Showcase of promising emerging tech companies.

- These are virtual "Meetings" NOT "webinars". All attendees can see and direct message all other attendees.

- Investor Polling: Investors can indicate their interest in each Presenting Company for post-event follow-up.

- We will publish a full list of all registrants - name, title, and company name to enhance networking.

All attendees must be pre-registered on this Eventbrite site.

Dear Investors,

Bladder cancer has remained one of the most expensive and persistent cancers on Earth—with limited treatment options and staggering recurrence rates.That ends now.

We’re excited to invite you to a private, invitation-only investor reception on Thursday, August 14 at 5:00PM ET in McLean, VA, featuring Combat Medical, a MedTech company revolutionizing the way we treat some of the world’s most expensive and recurring cancers.

Combat Medical is the first and only company to deliver effective, affordable, and tolerable treatment for the world’s most expensive cancers. The Company has developed two CE-marked drug delivery systems that use localized heat-enhanced chemotherapy (HIVEC®) to dramatically improve outcomes in bladder and peritoneal cancer treatment—areas with few options and high recurrence.

This breakthrough platform delivers chemotherapy directly to the tumor site using precision heat, improving drug absorption, immune response (including activation of natural killer cells), and patient comfort, while reducing side effects and impairing tumor growth. Already used in 35+ countries with 100,000+ treatments delivered, Combat is now entering the U.S. market.

The Investment Opportunity:

• Now raising: $5 million Series A

• $2.7 million already committed

• Funds support: $7M pivotal FDA trial and U.S. market entry

• Interim trial results expected end of 2026; final FDA approval targeted for 2029

• Valuation inflection point anticipated following interim data

• Comparable U.S. drug companies with weaker data have gone public at ~$1.8B valuations

• Backed by $20M to date, including $4M in non-dilutive government grants

• Self-funded operations and profitable international sales

Why Combat Medical?

Validated Technology with Global Traction

Combat’s HIVEC® platform has generated strong international commercial momentum, with $4.3M in 2024 revenue and positive EBITDA. The company’s “razorblade” model provides capital equipment free and monetizes single-use kits—90% of revenue—per treatment.

Massive Market with Urgent Need

Bladder cancer is the most expensive cancer to treat per patient. In the U.S. alone, 60,000 new NMIBC cases occur each year, with recurrence rates over 70%. Combat targets a $600M U.S. obtainable market within an $8B global TAM.

First-Mover Advantage with FDA Momentum

Combat has launched its FDA-reviewed HIVEC® Heat bladder trial, with interim data expected by late 2026. The company is uniquely positioned to lead the U.S. market for BCG-unresponsive NMIBC—a patient segment with few effective options.

Proven Team and Strategic Vision

Founded by Edward Bruce-White and Alberto Martinez, Combat combines medical expertise, commercial execution, and a clear path to exit—offering investors both meaningful impact and a de-risked path to value creation.

Why You Should Attend

This is a rare opportunity to back a clinically proven, revenue-generating MedTech platform poised for U.S. expansion, FDA approval, and significant investor upside. Join a select group of investors for a private, inside look at Combat Medical’s next chapter.

PLEASE NOTE: The minimum investment amount is $100,000

Event Details – Limited to Select Investors

📍 Location: The Capital Grille

1861 International Dr.

McLean, VA 22102

📅 Date: Thursday, August 14, 2025

🕔 Time: 5:00 PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

Light fare and refreshments will be served.

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to hosting you and sharing how Combat Medical is changing the future of cancer treatment—one patient, one system at a time.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Investors demand proof that your business can dominate the market, and customer growth is the ultimate proof point. Nail your customer acquisition, and you don’t just strengthen your pitch, you prove your business is scalable and unlock game-changing funding opportunities.

Join startup marketing experts, Buzzy Rocket, for a no-nonsense Masterclass that cuts through the BS and delivers battle-tested strategies to turn customer conversion into hard-hitting metrics that make investors sit up and take notice.

In this power-packed session, you’ll learn how to:

• Smash through common roadblocks like weak messaging and product-market misfits

• Prove your market validation

• Ignite customer engagement and retention to fuel unstoppable growth

• Convert traction into razor-sharp, investor-ready data that closes deals

Walk away armed with practical tools to bridge the gap between where you are and where you need to be. Expect Improvements in customer engagement and retention, the fuel that accelerates your funding runway.

Dear Investors,

Bladder cancer has remained one of the most expensive and persistent cancers on Earth—with limited treatment options and staggering recurrence rates.That ends now.

We’re excited to invite you to a private, invitation-only investor reception on Wednesday, August 13 at 5:30PM PT in New York City, NY, featuring Combat Medical, a MedTech company revolutionizing the way we treat some of the world’s most expensive and recurring cancers.

Combat Medical is the first and only company to deliver effective, affordable, and tolerable treatment for the world’s most expensive cancers. The Company has developed two CE-marked drug delivery systems that use localized heat-enhanced chemotherapy (HIVEC®) to dramatically improve outcomes in bladder and peritoneal cancer treatment—areas with few options and high recurrence.

This breakthrough platform delivers chemotherapy directly to the tumor site using precision heat, improving drug absorption, immune response (including activation of natural killer cells), and patient comfort, while reducing side effects and impairing tumor growth. Already used in 35+ countries with 100,000+ treatments delivered, Combat is now entering the U.S. market.

The Investment Opportunity:

• Now raising: $5 million Series A

• $2.7 million already committed

• Funds support: $7M pivotal FDA trial and U.S. market entry

• Interim trial results expected end of 2026; final FDA approval targeted for 2029

• Valuation inflection point anticipated following interim data

• Comparable U.S. drug companies with weaker data have gone public at ~$1.8B valuations

• Backed by $20M to date, including $4M in non-dilutive government grants

• Self-funded operations and profitable international sales

Why Combat Medical?

Validated Technology with Global Traction

Combat’s HIVEC® platform has generated strong international commercial momentum, with $4.3M in 2024 revenue and positive EBITDA. The company’s “razorblade” model provides capital equipment free and monetizes single-use kits—90% of revenue—per treatment.

Massive Market with Urgent Need

Bladder cancer is the most expensive cancer to treat per patient. In the U.S. alone, 60,000 new NMIBC cases occur each year, with recurrence rates over 70%. Combat targets a $600M U.S. obtainable market within an $8B global TAM.

First-Mover Advantage with FDA Momentum

Combat has launched its FDA-reviewed HIVEC® Heat bladder trial, with interim data expected by late 2026. The company is uniquely positioned to lead the U.S. market for BCG-unresponsive NMIBC—a patient segment with few effective options.

Proven Team and Strategic Vision

Founded by Edward Bruce-White and Alberto Martinez, Combat combines medical expertise, commercial execution, and a clear path to exit—offering investors both meaningful impact and a de-risked path to value creation.

Why You Should Attend

This is a rare opportunity to back a clinically proven, revenue-generating MedTech platform poised for U.S. expansion, FDA approval, and significant investor upside. Join a select group of investors for a private, inside look at Combat Medical’s next chapter.

PLEASE NOTE: The minimum investment amount is $100,000

Event Details – Limited to Select Investors

📍 Location: The Capital Grille

120 W 5st St,

New York, NY 10020

📅 Date: Wednesday, August 13, 2025

🕔 Time: 5:30 PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

Light fare and refreshments will be served.

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to hosting you and sharing how Combat Medical is changing the future of cancer treatment—one patient, one system at a time.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Dear Investors,

Bladder cancer has remained one of the most expensive and persistent cancers on Earth—with limited treatment options and staggering recurrence rates. That ends now.

We’re excited to invite you to a private, invitation-only investor reception on Tuesday, August 12 at 5:30PM PT in San Francisco, CA, featuring Combat Medical, a MedTech company revolutionizing the way we treat some of the world’s most expensive and recurring cancers.

Combat Medical is the first and only company to deliver effective, affordable, and tolerable treatment for the world’s most expensive cancers. The Company has developed two CE-marked drug delivery systems that use localized heat-enhanced chemotherapy (HIVEC®) to dramatically improve outcomes in bladder and peritoneal cancer treatment—areas with few options and high recurrence.

This breakthrough platform delivers chemotherapy directly to the tumor site using precision heat, improving drug absorption, immune response (including activation of natural killer cells), and patient comfort, while reducing side effects and impairing tumor growth. Already used in 35+ countries with 100,000+ treatments delivered, Combat is now entering the U.S. market.

The Investment Opportunity:

• Now raising: $5 million Series A

• $2.7 million already committed

• Funds support: $7M pivotal FDA trial and U.S. market entry

• Interim trial results expected end of 2026; final FDA approval targeted for 2029

• Valuation inflection point anticipated following interim data

• Comparable U.S. drug companies with weaker data have gone public at ~$1.8B valuations

• Backed by $20M to date, including $4M in non-dilutive government grants

• Self-funded operations and profitable international sales

Why Combat Medical?

Validated Technology with Global Traction

Combat’s HIVEC® platform has generated strong international commercial momentum, with $4.3M in 2024 revenue and positive EBITDA. The company’s “razorblade” model provides capital equipment free and monetizes single-use kits—90% of revenue—per treatment.

Massive Market with Urgent Need

Bladder cancer is the most expensive cancer to treat per patient. In the U.S. alone, 60,000 new NMIBC cases occur each year, with recurrence rates over 70%. Combat targets a $600M U.S. obtainable market within an $8B global TAM.

First-Mover Advantage with FDA Momentum

Combat has launched its FDA-reviewed HIVEC® Heat bladder trial, with interim data expected by late 2026. The company is uniquely positioned to lead the U.S. market for BCG-unresponsive NMIBC—a patient segment with few effective options.

Proven Team and Strategic Vision

Founded by Edward Bruce-White and Alberto Martinez, Combat combines medical expertise, commercial execution, and a clear path to exit—offering investors both meaningful impact and a de-risked path to value creation.

Why You Should Attend

This is a rare opportunity to back a clinically proven, revenue-generating MedTech platform poised for U.S. expansion, FDA approval, and significant investor upside. Join a select group of investors for a private, inside look at Combat Medical’s next chapter.

PLEASE NOTE: The minimum investment amount is $100,000

📍 Event Details – Limited to Select Investors

Location: Fogo de Chão Brazilian Steakhouse,

201 3rd St Suite 100,

San Francisco, CA 94103

Date: Tuesday, August 12, 2025

Time: 5:30 PM PT

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

Light fare and refreshments will be served.

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to hosting you and sharing how Combat Medical is changing the future of cancer treatment—one patient, one system at a time.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Join us for a thought-provoking and energizing fireside chat with Derek Coburn, bestselling author, entrepreneur, and co-founder of CADRE, as we explore a bold reimagining of life, work, and purpose beyond the outdated notion of retirement. This master class is especially relevant for professionals in their mid-40s to mid-60s who are starting to question the traditional script of deferring joy, freedom, and impact until age 65.

Have you ever asked yourself: Why am I sacrificing health, time with loved ones, and meaningful experiences now for the promise of “someday?” In this session, Derek will share powerful insights from his new book, “Let’s Retire Retirement,” which challenges the conventional retirement mindset and offers a more practical—and fulfilling—alternative. Instead of planning to stop working someday, learn how to “rewire” your life now so that you’re living richly in both meaning and money, without waiting.

We’ll explore how to create a life you never want to retire from, how to align your income model with the lifestyle you desire, and how to rethink success in a way that works now—not 20 years from now.

Key Takeaways:

• A modern redefinition of “retirement” that prioritizes health, purpose, and joy—now

• How to design a life where income, meaning, and flexibility coexist

• Strategies for mid-career professionals to shift from “accumulation mode” to “fulfillment mode”

• Tools for embracing continuous growth while still earning and contributing

• Actionable ideas to reclaim time and avoid burnout in your 40s, 50s, and 60s

About Derek Coburn:

Derek Coburn is a bestselling author and financial advisor with over 20 years of experience helping high-performing professionals build lives they don’t want to retire from. He is the author of Networking Is Not Working and Let’s Retire Retirement, and the co-founder of CADRE, an exclusive "un-networking" community for CEOs and entrepreneurs. Derek is a passionate connector, devoted husband and father, and an advocate for rethinking outdated notions of success and fulfillment.

Join us for CONNECTails networking event, a joint production of CONNECTpreneur and Group 3D. CONNECTpreneur is the premiere networking and professional development organization for over 30,000 Entrepreneurs, VCs and angels, CEOs, and other business leaders in the Mid-Atlantic Region.

CONNECTails is where our community comes together to meet, greet, learn about new opportunities, network, imbibe, and relax in a lively professional atmosphere.

The event is a great opportunity for start-up companies seeking funding to introduce themselves, meet with potential investors, network with future employees, and connect with quality service providers.

Registration:

• Attendees: Entrepreneurs Seeking Funding & Students - $35 in advance

• Attendee: Investors, Government - $45 in advance

• Attendee: Vendors and Service Providers - $75 in advance

EXCITING NEW VENUE!

This month we move the event to the rooftop cocktail party and networking space at:

Buena Vida Gastrolounge
2900 Wilson Boulevard
Arlington, VA 22201

Check out this link to relive our initial walk-through. It's a cool spot, perfect for a hot summer night!

Metro: Clarendon station on the Orange/Silver Line

• Parking: Street, and there's a lot right across the street at 1303 N Fillmore St, Arlington, VA 22201 (Atlantic Parking)

• Includes: First drink ticket, hot appetizers, swag, one door prize chance

• Dress: Professional casual

• Music: Classic Rock and Jazz

• Vibe: Select, friendly, positive, professional

Bring: Your own name badge from a previous event or conference. To this last point, a modest prize will be given to the attendee with the most improbable, random, or interesting name badge, subject entirely of course whims of the event organizers.

Our Honorary Hosts for the evening include Deb Hemingway, Managing Partner of Ecphora Capital. The Good Doctor Deb is an investor, entrepreneur, research scientist, strategic advisor, mover, shaker, and proven champion of start-ups in our region.

Carrie Zhang of Citrine Angels makes her Honorary Host debut this month. Carrie is an accomplished leader with extensive experience across the biotechnology and scientific community, and is committed to fostering innovation and strategic growth in our region.

Rounding out our awesome Honorary Host team are the Touchdown Twins Marty and Sotti Koev, founders of Koev Brothers Private Investor Group. The Koev Brothers focus on top performing early and later stage private operating companies and funds. They have expertise in private equity, bridge loans, capital introductions, and turnarounds.

All our Honorary Hosts look forward to meeting all attendees, talking shop, exploring investment opportunities, and enjoying a fun evening.

- -

Sponsorship and Entrepreneur Exhibitor slots are available. Send an email to Hank Dearden (hankd@iiid.com) for details and we'll take care of you right away.

Bring plenty of business cards, register today, we look forward to seeing you there!

NO REFUNDS

Join a select group of ambitious founders and savvy investors for a high-impact master class designed to give you an insider edge: how to create, identify, and leverage intellectual property (IP) that actually drives startup growth, attracts serious investment, and adds measurable value at exit.

This isn’t an IP 101 course. This is a deep dive into the real-world IP tactics used by high-performing startups—what to pursue, what to avoid, and how to wield IP as both a defensive shield and a growth engine.

You’ll discover:

• How top-tier startups use IP as a magnet for funding and M&A interest

• Why some patents boost valuations—while others just drain your burn rate

• Investor red flags: The costly IP pitfalls that can kill a deal before diligence begins

• How to neutralize third-party IP threats and avoid litigation traps

• What leading investors really want to see in an IP strategy—and how to deliver it

This session is designed for action. You’ll leave with a strategic IP checklist, investor-aligned messaging tactics, and a sharper lens for evaluating IP as an asset—not an expense.

⚠️ Seats are limited to maintain a high-caliber peer group and foster real discussion. Previous sessions have sold out quickly.

This is your chance to get ahead of the curve—before your next funding round or product launch.

About this Event:

CONNECTpreneur Virtual Rocket Pitch events are the World's Largest investor pitch events, with the greatest number of accredited investors, VCs, private investors and angels.

This will be our 133rd event (66th Virtual) over the last 14 years.

CONNECTpreneur is a bi-monthly networking mashup that has been attended by 30,000+ business leaders over the past 14 years. Our events are cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Program Highlights:

- "Virtual Networking" pre and post-program - via Private Message, and Breakout Rooms

- We feature Breakout Rooms after the Pitch portion of the events. Each Breakout Room is hosted by a Presenting Company. Attendees will be able to enter and leave any Breakout Room at their convenience.

- Who will be online? We expect 400+ business leaders, including 150+ CEOs & Founders, as well as 150+ angels & VCs from around the USA.

- "Rocket Pitch" Showcase of promising emerging tech companies.

- These are virtual "Meetings" NOT "webinars". All attendees can see and direct message all other attendees.

- Investor Polling: Investors can indicate their interest in each Presenting Company for post-event follow-up.

- We will publish a full list of all registrants - name, title, and company name to enhance networking.

All attendees must be pre-registered on this Eventbrite site.

Dear Investors,

Imagine a world where Alzheimer’s isn’t a life sentence but a treatable condition. NeuroEM is on the verge of making that a reality, and we invite you to be part of this breakthrough.

Join us for a private investor dinner on Wednesday, June 25 at 5:30PM PT in Palo Alto, CA, where you’ll gain early access to an opportunity poised to disrupt the $300B Alzheimer’s market.

Why You Should Attend

✔ First-Mover Advantage – Meet NeuroEM’s visionary team and discover how their FDA-designated Breakthrough Device is transforming Alzheimer’s treatment.

✔ A Game-Changing Solution – Backed by 10+ years of university research, 2 NIH grants, and 9 issued patents, this non-invasive device has clinically demonstrated cognitive improvement in Alzheimer’s patients within just two months.

✔ Network with Elite Investors – Connect with top-tier investors, family offices, and industry pioneers in an intimate, high-caliber setting.

The Science Behind NeuroEM

NeuroEM’s TEMT-RF (Transcranial Electro-Magnetic Treatment using Radio Frequencies) has shown remarkable success in clinical trials:

- 7 of 8 Alzheimer’s patients experienced cognitive improvement within just two months.

- Disrupts Alzheimer’s at its core by detoxifying the brain, reducing inflammation, and restoring cellular energy (ATP)—a trifecta never before achieved in Alzheimer’s treatment.

- 10 additional patents pending worldwide, with deep scientific validation from leading institutions and the NIH.

Why This Opportunity is Unique

The Alzheimer’s market is at a tipping point, and NeuroEM is first in line to redefine it.

- Raising $5M Seed Preferred (attractive pre-money valuation: $15M).

- Planned $5-10M Series A in 2025

- 55M+ patients worldwide, with healthcare systems spending 3x more on Alzheimer’s patients.

With the FDA’s Breakthrough Device designation, NeuroEM is positioned as an industry leader—offering a scalable, cost-effective alternative to pharmaceuticals with far superior results.

Event Details – Limited to Select Investors

📍 Location: Fleming's Steakhouse

180 El Camino Real Ste 2 Palo Alto, CA 94304

📅 Date: Wednesday, June 25, 2025

🕔 Time: 5:30PM PT

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of Alzheimer’s treatment.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor dinner featuring Intrommune, a consumer health company with a revolutionary approach to allergy prevention.

Intrommune’s patented oral mucosal immunotherapy (OMIT) platform delivers allergenic proteins via a simple, familiar routine: brushing your teeth. This daily-use toothpaste is designed to train the immune system and help prevent life-threatening food allergies—starting with peanuts and tree nuts.

This elegant solution bridges the gap between biotech and consumer health, offering a safe, effective, and scalable approach to a massive and underserved global market.

💡 The Investment Opportunity:

• Now raising $4 million

• Minimum investment: $100,000 (lower amounts may be considered at Management’s discretion)

• Early investors within 30 days receive preferential terms

• NASDAQ IPO targeted within 36 months

Why Intrommune?

Validated Science, Consumer Simplicity
In the published Phase 1 OMEGA study for peanut allergy, patients achieved 97% adherence with zero dropouts and no cases of anaphylaxis from the therapy—a rare combination of strong clinical results and unmatched user friendliness.

Enormous Market Need
Over 33 million Americans suffer from food allergies, yet treatment options remain limited. Early and consistent food exposure has been shown to decrease food allergies by over 80%. OMIT offers a daily, non-invasive food exposure toothpaste with wide appeal for parents, caregivers, and at-risk individuals.

First-Mover Advantage
No other company combines biotech-grade science with a consumer-ready delivery format—positioning Intrommune as the clear category creator in oral allergy prevention.

Experienced Leadership
CEO Michael Nelson brings decades of operational and financing experience in healthcare, and the company is advised by Dr. Sharon Chinthrajah, a nationally recognized allergy expert.

🎯 Why You Should Attend:

This is a rare opportunity to back a biotech-powered consumer product that’s validated, scalable, and de-risked—and to meet the team behind it in a private setting.

Join a select group of investors for an insider’s view into Intrommune’s next chapter and how this product could become a daily staple for millions of families.

📍 Event Details – Strictly Limited:

Location: Fogo de Chão
201 3rd St Suite 100,
San Francisco, CA 94103
Date: June 24, 2025
Time: 5:30pm PDT

This event is exclusively for accredited investors, family offices, and advisors.

📩 RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

Warm regards,

Tien Wong

CEO

Opus8, Inc.

Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor dinner featuring Intrommune, a consumer health company with a revolutionary approach to allergy prevention.

Intrommune’s patented oral mucosal immunotherapy (OMIT) platform delivers allergenic proteins via a simple, familiar routine: brushing your teeth. This daily-use toothpaste is designed to train the immune system and help prevent life-threatening food allergies—starting with peanuts and tree nuts.

This elegant solution bridges the gap between biotech and consumer health, offering a safe, effective, and scalable approach to a massive and underserved global market.

💡 The Investment Opportunity:

• Now raising $4 million

• Minimum investment: $100,000 (lower amounts may be considered at Management’s discretion)

• Early investors within 30 days receive preferential terms

• NASDAQ IPO targeted within 36 months

Why Intrommune?

Validated Science, Consumer Simplicity
In the published Phase 1 OMEGA study for peanut allergy, patients achieved 97% adherence with zero dropouts and no cases of anaphylaxis from the therapy—a rare combination of strong clinical results and unmatched user friendliness.

Enormous Market Need
Over 33 million Americans suffer from food allergies, yet treatment options remain limited. Early and consistent food exposure has been shown to decrease food allergies by over 80%. OMIT offers a daily, non-invasive food exposure toothpaste with wide appeal for parents, caregivers, and at-risk individuals.

First-Mover Advantage
No other company combines biotech-grade science with a consumer-ready delivery format—positioning Intrommune as the clear category creator in oral allergy prevention.

Experienced Leadership
CEO Michael Nelson brings decades of operational and financing experience in healthcare, and the company is advised by Dr. Sharon Chinthrajah, a nationally recognized allergy expert.

🎯 Why You Should Attend:

This is a rare opportunity to back a biotech-powered consumer product that’s validated, scalable, and de-risked—and to meet the team behind it in a private setting.

Join a select group of investors for an insider’s view into Intrommune’s next chapter and how this product could become a daily staple for millions of families.

📍 Event Details – Strictly Limited:

Location: Del Frisco’s Double Eagle Steakhouse
10250 Santa Monica Blvd., Suite 1700,
Los Angeles, CA 90067
Date: June 23, 2025
Time: 5:30pm PDT

This event is exclusively for accredited investors, family offices, and advisors.

📩 RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

Warm regards,

Tien Wong

CEO

Opus8, Inc.

In today’s fast-moving investment landscape, raising capital is more competitive than ever. Founders who succeed aren’t just lucky — they’re strategic, prepared, and investor-ready.Join Anthony Millin — a trusted authority with decades of experience as a venture investor, startup attorney, serial entrepreneur, and CEO/Co-Founder of My NEXT Raise — for this high-impact Masterclass. Anthony has raised capital himself, advised hundreds of founders, and built a platform designed specifically to help startups succeed.

In this one-time-only session, you'll gain:

✅ Authority-backed insights from someone who’s been in the fundraising trenches — and won
✅ A behind-the-scenes look at what top investors actually look for (most founders miss this)
✅ Proven tools and strategies from My NEXT Raise, used by hundreds of successful startups
✅ A clear, step-by-step path to becoming investor-ready — with legal and business essentials aligned
✅ An opportunity to connect with Anthony and ask questions directly
✅ Access to exclusive fundraising tools — only available to attendees

Whether you're preparing for your first seed round or scaling toward Series A, this session will arm you with the knowledge, credibility, and confidence to raise capital effectively — and close with conviction.

Kick Off BIO Week 2025 with an Exclusive Investor Networking Reception!

Start your BIO Week experience with an exceptional networking opportunity designed to connect healthcare and life sciences investors with leading biotech and life sciences entrepreneurs.

Why Attend?

• Meet dozens of top-tier investors and influential industry leaders in an intimate, high-value setting.

• Connect with innovative companies driving breakthroughs in healthcare and biotech.

• Expand your network with like-minded professionals, entrepreneurs, and decision-makers.

Hosted annually by CONNECTpreneur and Opus8., this event offers an exclusive chance to build relationships that can shape the future of healthcare and life sciences.

Event Details
📅 Monday, June 16, 2025
📍 Alma Gaucha Prime Brazilian Steakhouse,

401 D St., Boston, MA, 02210
🍴 Enjoy light fare and unlimited premium beverages in a relaxed, upscale atmosphere.

Who Should Attend?

• VCs and Accredited investors passionate about healthcare, biotech, and life sciences.

• Entrepreneurs and founders seeking capital and partnerships.

Attendance will be Limited!

This event is highly sought after, with limited spots available to ensure meaningful connections. Reserve your seat today before space runs out!

Take the First Step
Discover the partnerships and insights that could define your 2025.

👉 Register Now to secure your spot and begin your BIO Week on the right note!

Sponsorship and Exhibitor Opportunities

Elevate your brand in front of a highly curated audience of investors and industry leaders. For more information, please contact Skylar Rallison at srallison@opus8.com.

Come join us in Tysons Corner, VA for a CONNECTpreneur Forum Event like you've never seen before!

CONNECTpreneur is a bi-monthly networking mashup, which has been attended by 30,000+ business leaders over the past 14 years and Is cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Space is very limited at this venue, and we expect another Sold Out crowd, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- Showcase of emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- We are capping attendance at 250 business leaders, including 75+ angels and private investors, family offices, etc.

- Speakers who are deeply rooted in our community, sharing their insider knowledge and showcasing the innovation thriving in our region.

- Heavy networking before, during, and after the event

Dear Investors,

Over 80% of Earth—oceans, ice, dense jungles, underground tunnels, most man-made infrastructures —has long been a dead zone for wireless connectivity.

That changes now.

Using proprietary Surface Electromagnetic Wave technology, Saltenna became the first to transmit high-bandwidth RF signals without line of sight— oceans, ice, dense jungles, underground tunnels, and most man-made infrastructures.

The implications? Enormous. The addressable markets—oil & gas, defense, mining, shipping & logistics, telecom, smart cities—span trillions in infrastructure investment.

This is a first-mover advantage with patented IP and government backing.

A DARPA Program Manager described it as "the most exciting breakthrough in the Electromagnetic Spectrum in the last 60 years."

Now we’re raising $5M in a Series A round to seize the opportunity ahead.

WHY SALTENNA NOW

🔒 Deep IP Moat

· 4 patents granted, 21 pending, 100+ patentable technologies

· Filing ~1 new patent per week

🚀 Real Traction

· $7M+ in non-dilutive funding in the past 7 months (DTRA, USSOCOM, Air Force, Navy)

· Active engagements with Kongsberg Maritime, TechnipFMC and other companies for oil & gas subsea operation

· 6 Letters of Support from major USAF & Space Force bases

🧭 Massive Market Potential

Saltenna enables connectivity in multi-trillion-dollar markets:

· Oil & Gas: Subsea, underground, remote operations

· Defense & Security: Tactical comms, drones, submarines, tunnels & bunkers

· Telecom & Logistics: Cargo tracking, last-mile, hangars, ports

· Smart Infrastructure: Cities, aviation, robotics, manufacturing, depots, IIoT

🌎 Vast Untapped Terrain

Saltenna unlocking the 83–84% of the Earth previously unconnectable:

· 71% water

· 3% polar ice

· 9–10% forested and dense terrain

· Subterranean (tunnels, bunkers, caves)

· Most man-made metal infrastructures

Series A Target: $5M

We are raising strategic capital to

📡 $1.0M – Global IP expansion 🔬 $1.5M – Advanced R&D

🧪 $1.0M – Finalize productization & regulatory milestones

🌍 $1.0M – Strategic partnerships & BD

🔄 $0.5M – Operational growth and working capital

Initial $1.5M seed funding was led by Saltenna’s founders, Fairfax Founders Fund (FFF), Virginia Innovation Partnership Corporation (VIPC), and Virginia Venture Partners (VVP).

This is a rare opportunity to invest in a breakthrough platform redefining global wireless communications.

If you're an accredited investor, advisor, or strategic partner, we’d love to connect.

Warm regards,

Opus8 Team

Virtual Rocket Pitch + Power Networking by CONNECTpreneur Investor Network

Thursday, May 29, 2025, 11:00am EDT

We will email you the LINK to this special event on the evening of May 28th, as well as the morning of May 29th.

About this Event:

CONNECTpreneur Virtual Rocket Pitch events are the World's Largest investor pitch events, with the greatest number of accredited investors, VCs, private investors and angels.

This will be our 131st event (65th Virtual) over the last 14 years.

CONNECTpreneur is a bi-monthly networking mashup that has been attended by 30,000+ business leaders over the past 14 years. Our events are cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Program Highlights:

- "Virtual Networking" pre and post-program - via Private Message, and Breakout Rooms

- We feature Breakout Rooms after the Pitch portion of the events. Each Breakout Room is hosted by a Presenting Company. Attendees will be able to enter and leave any Breakout Room at their convenience.

- Who will be online? We expect 400+ business leaders, including 150+ CEOs & Founders, as well as 150+ angels & VCs from around the USA.

- "Rocket Pitch" Showcase of promising emerging tech companies.

- These are virtual "Meetings" NOT "webinars". All attendees can see and direct message all other attendees.

- Investor Polling: Investors can indicate their interest in each Presenting Company for post-event follow-up.

- We will publish a full list of all registrants - name, title, and company name to enhance networking.

All attendees must be pre-registered on this Eventbrite site.

Join a select group of founders, operators, and investors for a behind-the-scenes masterclass on what it really takes to raise millions through equity crowdfunding—when the market is working against you.

This isn’t a generic fundraising talk. It’s a tactical breakdown of how Sen-Jam Pharmaceutical raised $3.4 million from 1,500+ investors in just a few months, led by CEO Jim Iversen.

You’ll walk away with real-world insights, proven frameworks, and momentum-building strategies that actually work in today’s volatile funding landscape.

You’ll discover:

• How to create a campaign that converts—from pitch to close

• What makes an offer irresistible to retail investors (and how to frame it)

• How to build social proof fast—and use it to drive urgency and action

• Why storytelling beats spreadsheets when it comes to raising at scale

• How to maintain momentum from pre-launch to post-close

• The investor follow-up strategy that turns one-time backers into brand champions

• What Jim would do differently—and what he’ll double down on next time

This session is built for:

• Founders actively raising or exploring crowdfunding as a funding channel

• Startups looking to build buzz and raise capital from a broad investor base

• Investors and advisors who want to understand the mechanics behind successful campaigns

• Anyone looking for a step-by-step look into what makes crowdfunding work—when done right

🚨 Spots are limited to keep the group focused and high-value. Prior sessions have filled fast.If you’re planning a raise—or want to sharpen your fundraising playbook—don’t miss this.

Secure your spot now.

Dear Investors,

Over 80% of Earth—oceans, ice, dense jungles, underground tunnels, most man-made infrastructures —has long been a dead zone for wireless connectivity.

That changes now.

Using proprietary Surface Electromagnetic Wave technology, Saltenna became the first to transmit high-bandwidth RF signals without line of sight— oceans, ice, dense jungles, underground tunnels, and most man-made infrastructures.

The implications? Enormous. The addressable markets—oil & gas, defense, mining, shipping & logistics, telecom, smart cities—span trillions in infrastructure investment.

This is a first-mover advantage with patented IP and government backing.

A DARPA Program Manager described it as "the most exciting breakthrough in the Electromagnetic Spectrum in the last 60 years."

Now we’re raising $5M in a Series A round to seize the opportunity ahead.

WHY SALTENNA NOW

🔒 Deep IP Moat

· 4 patents granted, 21 pending, 100+ patentable technologies

· Filing ~1 new patent per week

🚀 Real Traction

· $7M+ in non-dilutive funding in the past 7 months (DTRA, USSOCOM, Air Force, Navy)

· Active engagements with Kongsberg Maritime, TechnipFMC and other companies for oil & gas subsea operation

· 6 Letters of Support from major USAF & Space Force bases

🧭 Massive Market Potential

Saltenna enables connectivity in multi-trillion-dollar markets:

· Oil & Gas: Subsea, underground, remote operations

· Defense & Security: Tactical comms, drones, submarines, tunnels & bunkers

· Telecom & Logistics: Cargo tracking, last-mile, hangars, ports

· Smart Infrastructure: Cities, aviation, robotics, manufacturing, depots, IIoT

🌎 Vast Untapped Terrain

Saltenna unlocking the 83–84% of the Earth previously unconnectable:

· 71% water

· 3% polar ice

· 9–10% forested and dense terrain

· Subterranean (tunnels, bunkers, caves)

· Most man-made metal infrastructures

Series A Target: $5M

We are raising strategic capital to

📡 $1.0M – Global IP expansion 🔬 $1.5M – Advanced R&D

🧪 $1.0M – Finalize productization & regulatory milestones

🌍 $1.0M – Strategic partnerships & BD

🔄 $0.5M – Operational growth and working capital

Initial $1.5M seed funding was led by Saltenna’s founders, Fairfax Founders Fund (FFF), Virginia Innovation Partnership Corporation (VIPC), and Virginia Venture Partners (VVP).

This is a rare opportunity to invest in a breakthrough platform redefining global wireless communications.

If you're an accredited investor, advisor, or strategic partner, we’d love to connect.

Warm regards,

Opus8 Team

Dear Investors,

Join us for an exclusive opportunity to connect with World Tree Technologies Inc., a company poised to transform the $170B North American lumber market with sustainable, high-growth timber investments.

Why World Tree?

🌱 Sustainable + Profitable – The leading grower of Empress Splendor trees, the world’s fastest-growing hardwood, with 7,000+ acres across five countries.

📈 Massive Market Opportunity – North American specialty lumber demand is expected to triple by 2050, made even more acute by permanent shortages in pine, cedar, ash and redwood.

💰 Proven Financial Traction – Revenue-positive at $2.5M (2025) and targeting $8M+ annual sales by 2027 with 100%+ annual profit growth.

🛠️ Strong Industry Demand – 13 active buyers ($6/bft), 32 in trial, and full presale of 2026/2027 harvests already secured.

🌍 Impact-Driven Growth – Regenerative forestry that restores soil, sequesters carbon, and creates rural jobs—blending profit with purpose.

🔬 Deep R&D & Strong Foundation – $17M raised, zero debt, 9 years of R&D, and $300M in planted timber value, including 8 proprietary genetic varieties for superior yield.

🏆 Experienced Leadership – Experts in forestry, agriculture, and geospatial technology, with a track record in managing multibillion-dollar budgets.

Investment Opportunity

✅ Raising $3–4M in equity, building on $3.2M already raised in the Friends & Family round.
✅ Expanding forestry assets to 28,000+ acres and accelerating institutional partnerships.
✅ Scaling lumber sales to meet surging demand and drive profitability.
✅ EBITDA-positive by 2027, with continued rapid profit growth.

Why Now?

With a fully presold harvest, rising specialty lumber prices, and a once-in-a-generation market shift, World Tree offers a rare first-mover advantage in sustainable forestry investments.

Event Details – Limited to Select Investors

📍 Location: The Capital Grille

1861 International Drive,

McLean, VA 22102

📅 Date: Wednesday, May 7, 2025

🕔 Time: 5:30PM ET

💡 Limited seats available—RSVP now to secure your place at the table.

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of the North American lumber market.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Dear Investors,

Join us for an in-person investor presentation on May 6th at 11:30am EDT to learn about AuraVax Therapeutics, Inc.—pioneering a first-in-class solution for respiratory viruses.

Why AuraVax Matters

AuraVax is developing NanoSTING, a groundbreaking broad-acting treatment and prevention for respiratory pathogens, including influenza, SARS-CoV-2, and RSV. Unlike existing treatments, NanoSTING works even against evolving strains and could protect high-risk populations like seniors, immunocompromised individuals, and those with chronic diseases.

Key Highlights

✅ First-in-Class: Broad-acting treatment for multiple respiratory viruses—unaffected by mutations.
✅ Biodefense + Public Health: Military and civilian applications unlock multiple funding sources.
✅ Accelerated Pathway: BARDA contract awarded for H5N1 vaccine candidate; part of the BARDA Vital Hub accelerator.
✅ Strategic Partnerships: Collaborating with Codagenix and Defender Pharmaceuticals to develop intranasal vaccines and military countermeasures.
✅ Market Potential: $20B addressable market with high growth potential.
✅ First Clinical Trials: Planned for 2026.

The Opportunity

Respiratory viruses cause over $25B in annual economic loss in the U.S. NanoSTING offers a unique dual-use solution for seasonal outbreaks and biodefense, ensuring military readiness and public health resilience.

Technology Pipeline

1. NanoSTING-001 – Targets mild-to-moderate infections in high-risk groups; potential for military biodefense applications under the FDA’s Animal Rule.

2. NanoSTING-002 – First-in-class mucosal adjuvant for intranasal vaccines, improving immunity and blocking transmission.

Investment Details

🔹 Raising $4.5M via SAFE, with approx. $2 million already circled
🔹 Minimum investment: $100K.
🔹 Potential Exit: Licensing NanoSTING to vaccine partners and for biodefense applications within 3–4 years.

Why Now

With dual-use potential and strategic government backing, AuraVax is positioned to disrupt a $20B+ market. Don’t miss the chance to be part of this high-growth opportunity.

Event Details – Limited to Select Investors

📍 Location: Online via Zoom

📅 Date: Tuesday, May 6, 2025

🕔 Time: 11:30AM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of prevention for respiratory pathogens.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Virtual Rocket Pitch + Power Networking by CONNECTpreneur Investor Network

Thursday, April 24, 2025, 11:00am EDT

We will email you the LINK to this special event on the evening of April 23rd, as well as the morning of April 24th.

About this Event:

CONNECTpreneur Virtual Rocket Pitch events are the World's Largest investor pitch events, with the greatest number of accredited investors, VCs, private investors and angels.

This will be our 130th event (64th Virtual) over the last 14 years.

CONNECTpreneur is a bi-monthly networking mashup that has been attended by 30,000+ business leaders over the past 14 years. Our events are cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Program Highlights:

- "Virtual Networking" pre and post-program - via Private Message, and Breakout Rooms

- We feature Breakout Rooms after the Pitch portion of the events. Each Breakout Room is hosted by a Presenting Company. Attendees will be able to enter and leave any Breakout Room at their convenience.

- Who will be online? We expect 400+ business leaders, including 150+ CEOs & Founders, as well as 150+ angels & VCs from around the USA.

- "Rocket Pitch" Showcase of promising emerging tech companies.

- These are virtual "Meetings" NOT "webinars". All attendees can see and direct message all other attendees.

- Investor Polling: Investors can indicate their interest in each Presenting Company for post-event follow-up.

- We will publish a full list of all registrants - name, title, and company name to enhance networking.

All attendees must be pre-registered on this Eventbrite site.

Dear Investors,

Imagine a world where Alzheimer’s isn’t a life sentence but a treatable condition. NeuroEM is on the verge of making that a reality, and we invite you to be part of this breakthrough.

Join us for a private investor virtual meeting on Thursday, April 17 at 11:30AM ET, where you’ll gain early access to an opportunity poised to disrupt the $300B Alzheimer’s market.

Why You Should Attend

✔ First-Mover Advantage – Meet NeuroEM’s visionary team and discover how their FDA-designated Breakthrough Device is transforming Alzheimer’s treatment.

✔ A Game-Changing Solution – Backed by 10+ years of university research, 2 NIH grants, and 9 issued patents, this non-invasive device has clinically demonstrated cognitive improvement in Alzheimer’s patients within just two months.

✔ Network with Elite Investors – Connect with top-tier investors, family offices, and industry pioneers in an intimate, high-caliber setting.

The Science Behind NeuroEM

NeuroEM’s TEMT-RF (Transcranial Electro-Magnetic Treatment using Radio Frequencies) has shown remarkable success in clinical trials:

- 7 of 8 Alzheimer’s patients experienced cognitive improvement within just two months.

- Disrupts Alzheimer’s at its core by detoxifying the brain, reducing inflammation, and restoring cellular energy (ATP)—a trifecta never before achieved in Alzheimer’s treatment.

- 10 additional patents pending worldwide, with deep scientific validation from leading institutions and the NIH.

Why This Opportunity is Unique

The Alzheimer’s market is at a tipping point, and NeuroEM is first in line to redefine it.

- Raising $5M Seed Preferred (attractive pre-money valuation: $15M).

- Planned $5-10M Series A in 2025

- 55M+ patients worldwide, with healthcare systems spending 3x more on Alzheimer’s patients.

With the FDA’s Breakthrough Device designation, NeuroEM is positioned as an industry leader—offering a scalable, cost-effective alternative to pharmaceuticals with far superior results.

Event Details – Limited to Select Investors

📍 Location: Online via Zoom

📅 Date: Thursday, April 17, 2025

🕔 Time: 11:30AM ET

⚠️ Exclusive Invite-Only Event⚠️

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of Alzheimer’s treatment.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Dear Investors,

Join us for an in-person investor presentation on April 3rd at 5:30pm EDT to learn about AuraVax Therapeutics, Inc.—pioneering a first-in-class solution for respiratory viruses.

Why AuraVax Matters

AuraVax is developing NanoSTING, a groundbreaking broad-acting treatment and prevention for respiratory pathogens, including influenza, SARS-CoV-2, and RSV. Unlike existing treatments, NanoSTING works even against evolving strains and could protect high-risk populations like seniors, immunocompromised individuals, and those with chronic diseases.

Key Highlights

✅ First-in-Class: Broad-acting treatment for multiple respiratory viruses—unaffected by mutations.
✅ Biodefense + Public Health: Military and civilian applications unlock multiple funding sources.
✅ Accelerated Pathway: BARDA contract awarded for H5N1 vaccine candidate; part of the BARDA Vital Hub accelerator.
✅ Strategic Partnerships: Collaborating with Codagenix and Defender Pharmaceuticals to develop intranasal vaccines and military countermeasures.
✅ Market Potential: $20B addressable market with high growth potential.
✅ First Clinical Trials: Planned for 2026.

The Opportunity

Respiratory viruses cause over $25B in annual economic loss in the U.S. NanoSTING offers a unique dual-use solution for seasonal outbreaks and biodefense, ensuring military readiness and public health resilience.

Technology Pipeline

1. NanoSTING-001 – Targets mild-to-moderate infections in high-risk groups; potential for military biodefense applications under the FDA’s Animal Rule.

2. NanoSTING-002 – First-in-class mucosal adjuvant for intranasal vaccines, improving immunity and blocking transmission.

Investment Details

🔹 Raising $4.5M via SAFE
🔹 Minimum investment: $100K.
🔹 Potential Exit: Licensing NanoSTING to vaccine partners and for biodefense applications within 3–4 years.

Why Now

With dual-use potential and strategic government backing, AuraVax is positioned to disrupt a $20B+ market. Don’t miss the chance to be part of this high-growth opportunity.

Event Details – Limited to Select Investors

📍 Location: Fogo de Chão

1775 Tysons Blvd Suite 50,

Tysons, VA 22102

📅 Date: Thursday, April 3, 2025

🕔 Time: 5:30PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of prevention for respiratory pathogens.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Dear Investors,

Imagine a world where Alzheimer’s isn’t a life sentence but a treatable condition. NeuroEM is on the verge of making that a reality, and we invite you to be part of this breakthrough.

Join us for a private investor dinner on Thursday, March 27 at 5:30PM ET in Tysons Corner, Virginia, where you’ll gain early access to an opportunity poised to disrupt the $300B Alzheimer’s market.

Why You Should Attend

✔ First-Mover Advantage – Meet NeuroEM’s visionary team and discover how their FDA-designated Breakthrough Device is transforming Alzheimer’s treatment.

✔ A Game-Changing Solution – Backed by 10+ years of university research, 2 NIH grants, and 9 issued patents, this non-invasive device has clinically demonstrated cognitive improvement in Alzheimer’s patients within just two months.

✔ Network with Elite Investors – Connect with top-tier investors, family offices, and industry pioneers in an intimate, high-caliber setting.

The Science Behind NeuroEM

NeuroEM’s TEMT-RF (Transcranial Electro-Magnetic Treatment using Radio Frequencies) has shown remarkable success in clinical trials:

- 7 of 8 Alzheimer’s patients experienced cognitive improvement within just two months.

- Disrupts Alzheimer’s at its core by detoxifying the brain, reducing inflammation, and restoring cellular energy (ATP)—a trifecta never before achieved in Alzheimer’s treatment.

- 10 additional patents pending worldwide, with deep scientific validation from leading institutions and the NIH.

Why This Opportunity is Unique

The Alzheimer’s market is at a tipping point, and NeuroEM is first in line to redefine it.

- Raising $5M Seed Preferred (attractive pre-money valuation: $15M).

- Planned $5-10M Series A in 2025

- 55M+ patients worldwide, with healthcare systems spending 3x more on Alzheimer’s patients.

With the FDA’s Breakthrough Device designation, NeuroEM is positioned as an industry leader—offering a scalable, cost-effective alternative to pharmaceuticals with far superior results.

Event Details – Limited to Select Investors

📍 Location: Tysons Corner, VA (venue will be confirmed upon Registration)

📅 Date: Thursday, March 27, 2025

🕔 Time: 5:30PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of Alzheimer’s treatment.

Best regards,

Tien Wong

CEO

Opus8, Inc.

Virtual Rocket Pitch + Power Networking by CONNECTpreneur Investor Network

Thursday, March 27, 2025, 11:00am EDT

We will email you the LINK to this special event on the evening of March 26th, as well as the morning of March 27th.

About this Event:

CONNECTpreneur Virtual Rocket Pitch events are the World's Largest investor pitch events, with the greatest number of accredited investors, VCs, private investors and angels.

This will be our 129th event (63rd Virtual) over the last 14 years.

CONNECTpreneur is a bi-monthly networking mashup that has been attended by 30,000+ business leaders over the past 14 years. Our events are cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Program Highlights:

- "Virtual Networking" pre and post-program - via Private Message, and Breakout Rooms

- We feature Breakout Rooms after the Pitch portion of the events. Each Breakout Room is hosted by a Presenting Company. Attendees will be able to enter and leave any Breakout Room at their convenience.

- Who will be online? We expect 400+ business leaders, including 150+ CEOs & Founders, as well as 150+ angels & VCs from around the USA.

- "Rocket Pitch" Showcase of promising emerging tech companies.

- These are virtual "Meetings" NOT "webinars". All attendees can see and direct message all other attendees.

- Investor Polling: Investors can indicate their interest in each Presenting Company for post-event follow-up.

- We will publish a full list of all registrants - name, title, and company name to enhance networking.

All attendees must be pre-registered on this Eventbrite site.

CONNECTpreneur Forums are bi-monthly in person networking mashups, which have been attended by over 30,000 business leaders over the past 13 years.

Space is very limited at this venue, and this will another Sold Out in person event, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- We are capping attendance at 150+ business leaders, including 75+ angels and private investors, family offices, etc.

- Showcase of Emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- Heavy networking before, during, and after the event

Beverages and light fare will be provided.

Dear Esteemed Friends and Investors,

We are thrilled to invite you to a virtual Private Investor Presentation on Tuesday, March 4, at 11:30 AM EST, where we’ll introduce ICaPath—a company at the forefront of transforming cancer treatment.

In this exclusive session, you will get a first-look at one of the most disruptive immunotherapy delivery platforms in the Biotech industry. ICaPath is tackling the long-standing challenges of systemic delivery and targeted therapy failures in metastatic solid tumors, with an innovation poised to transform cancer care.

Why Attend?

• ICaPath’s approach is a game-changer in the immunotherapy space, offering a novel drug-delivery platform with the potential to reverse decades of treatment failures. By attending this presentation, you’ll be among the first to learn about this revolutionary technology and its future potential.

• As we approach our Series A round, we are offering exclusive access to this early investment opportunity. Seats are limited and demand is high—don’t miss your chance to get in early on this groundbreaking biotech venture.

• ICaPath is already seeing significant momentum in the industry. The company has secured $8.5 million in funding and major institutional backing, with a lead investor committing $3 million to the Series A round. Their partnerships with top-tier clinical sites, including Johns Hopkins’ NCI-designated program, further validate the credibility and potential of this company.

• With a $70 billion market opportunity, ICaPath’s innovations aim to tackle some of the most challenging cancers—Melanoma, Soft Tissue Sarcoma, and Renal Cell Carcinoma, with plans to address pediatric cancers. Your investment doesn’t just promise financial returns—it could also transform the lives of millions of cancer patients worldwide.

Key Investment Highlights

• Revolutionary Drug Delivery Platform: ICaPath is the only company offering systemic delivery of cytokines through PLGA nanoparticles, a unique approach that enhances treatment effectiveness while reducing side effects.

• Massive Market Potential: With a total addressable market (TAM) of $70 billion, ICaPath’s solution is ideally positioned for combination therapies, further expanding its reach and efficacy.

• Unmatched IP & Licensing Potential: The company holds a global “Composition of Matter” patent for cytokines loaded in PLGA nanoparticles. ICaPath’s strategic licensing plans are poised to generate millions in non-dilutive revenues from big pharma, with additional funding for FDA trials in key oncology indications.

• Expert Leadership: The ICaPath management team brings decades of expertise in drug development, clinical trials, and licensing deals. Led by a CEO with an exceptional track record of successfully guiding biotech companies to IPO or strategic acquisition, ICaPath’s leadership is committed to delivering exceptional shareholder returns.

• Near-Term Exit Potential: ICaPath is targeting a liquidity event within 2-3 years, offering the potential for early returns through a public offering or strategic acquisition.

A Proven Track Record of Success

• Funding Commitment: With $8.5 million already invested, ICaPath is currently raising an additional $5 million in Series A funding, with a committed lead investor contributing $3 million. $2 million of this round is still available—position yourself now to join an already-oversubscribed round.

• Accelerated Path to Clinical Trials: The company has secured GMP manufacturing for its IND submissions and has partnered with Johns Hopkins for first-in-human trials, ensuring a fast track for clinical development.

Don’t miss your chance to be part of this industry-transforming opportunity.

We look forward to your participation on March 4. Secure your spot today and position yourself for the next wave of investment success!

Location

Online via Zoom

If you would like more information such as the Company's executive summary and/or investment deck, please email Skylar Rallison at srallison@opus8.com.

We will provide a confirmation email and a calendar invitation after you register.

Thanks much and all the best,

The Opus8 Team